Telix Pharmaceuticals (NASDAQ:TLX) Announces Earnings Results

Key Points

• Telix Pharmaceuticals reported quarterly EPS of $0.05, beating the $0.04 consensus estimate by $0.01. Revenue totaled $238.5 million, below the $479.63 million consensus forecast.
• Shares rose 2.0% to open at $12.12, near the company’s 52-week high of $12.60. The stock has gained above both its 50-day and 200-day moving averages.
• Analysts maintain a generally positive outlook, with a consensus rating of “Moderate Buy” and an average price target of $20.40, despite recent rating changes including an RBC downgrade to “sector perform.”

Telix Pharmaceuticals (NASDAQ:TLX - Get Free Report) announced its earnings results on Thursday. The company reported $0.05 EPS for the quarter, topping the consensus estimate of $0.04 by $0.01, FiscalAI reports. The business had revenue of $238.50 million for the quarter, compared to the consensus estimate of $479.63 million.

Telix Pharmaceuticals Trading Up 2.0%

Shares of Telix Pharmaceuticals stock opened at $12.12 on Thursday. The company's 50 day moving average price is $10.87 and its two-hundred day moving average price is $9.60. Telix Pharmaceuticals has a fifty-two week low of $6.28 and a fifty-two week high of $12.60. The company has a debt-to-equity ratio of 1.08, a quick ratio of 1.27 and a current ratio of 1.43.

Analysts Set New Price Targets

A number of brokerages recently issued reports on TLX. Royal Bank Of Canada downgraded Telix Pharmaceuticals from an "outperform" rating to a "sector perform" rating in a research report on Friday, July 17th. Weiss Ratings reiterated a "sell (d)" rating on shares of Telix Pharmaceuticals in a research note on Friday, July 17th. Citigroup reissued a "buy" rating on shares of Telix Pharmaceuticals in a report on Thursday. Wedbush restated an "outperform" rating and set a $22.00 target price on shares of Telix Pharmaceuticals in a research note on Monday, July 6th. Finally, HC Wainwright reiterated a "buy" rating and issued a $20.00 target price on shares of Telix Pharmaceuticals in a research report on Tuesday, July 7th. One equities research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Telix Pharmaceuticals presently has an average rating of "Moderate Buy" and a consensus target price of $20.40.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of TLX. Russell Investments Group Ltd. acquired a new stake in shares of Telix Pharmaceuticals during the 2nd quarter valued at $975,000. Jane Street Group LLC bought a new position in Telix Pharmaceuticals in the second quarter valued at about $564,000. IHT Wealth Management LLC acquired a new stake in shares of Telix Pharmaceuticals during the second quarter valued at about $213,000. Rhumbline Advisers grew its holdings in shares of Telix Pharmaceuticals by 117.3% during the third quarter. Rhumbline Advisers now owns 2,579 shares of the company's stock worth $25,000 after purchasing an additional 1,392 shares during the last quarter. Finally, JPMorgan Chase & Co. bought a new stake in shares of Telix Pharmaceuticals during the third quarter worth about $243,000.

Telix Pharmaceuticals Company Profile

Telix Pharmaceuticals NASDAQ: TLX is a clinical-stage biopharmaceutical company focused on the development and commercialization of molecularly targeted radiopharmaceuticals for the diagnosis and treatment of cancer. Leveraging expertise in radiochemistry, nuclear medicine and oncology, Telix aims to address unmet clinical needs across a range of tumor types by pairing diagnostic imaging agents with therapeutic radionuclides.

The company’s pipeline spans both imaging and therapeutic candidates.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source